InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,949.66
(
0.25%
)
Post# of 704570
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

bobirw

Send PM Follow Ignore
Followers 142
Posts 66785
Boards Moderated 0
Alias Born 01/06/2004

bobirw

Re: None

Monday, 09/18/2017 12:37:59 PM

Monday, September 18, 2017 12:37:59 PM

Post# of 704570
NBRV Wedbush calls Nabriva data 'giant leap,' ups target to $21
Wedbush analyst Robert Driscoll raised his price target for Nabriva Therapeutics to $21 from $13 after the company's Phase 3 study for lefamulin against pneumonia met the primary endpoint. The analyst calls the data a "giant leap" for lefamulin. He has an Outperform rating on Nabriva. The shares in midday trading are up 37% to $9.43.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up